Pfizer (NYSE:PFE) Price Target Raised to $32.00

Pfizer (NYSE:PFE) had its price target lifted by HSBC from $29.00 to $32.00 in a research report released on Tuesday,Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

A number of other research analysts also recently weighed in on the company. Morgan Stanley dropped their target price on Pfizer from $32.00 to $28.00 and set an “equal weight” rating on the stock in a research report on Friday, December 12th. UBS Group started coverage on shares of Pfizer in a research report on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target for the company. Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Wednesday, December 17th. Daiwa Securities Group downgraded shares of Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 price objective on the stock. in a report on Thursday, February 12th. Finally, Citigroup assumed coverage on shares of Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $28.14.

Pfizer Trading Up 0.3%

NYSE:PFE opened at $27.40 on Tuesday. The company has a market cap of $155.78 billion, a PE ratio of 20.14 and a beta of 0.47. The company has a current ratio of 1.16, a quick ratio of 0.87 and a debt-to-equity ratio of 0.71. The company has a 50 day simple moving average of $26.65 and a two-hundred day simple moving average of $25.59. Pfizer has a 12 month low of $20.92 and a 12 month high of $27.94.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same period in the prior year, the firm earned $0.63 EPS. The company’s revenue was down 1.2% compared to the same quarter last year. Research analysts forecast that Pfizer will post 2.95 earnings per share for the current year.

Hedge Funds Weigh In On Pfizer

Hedge funds have recently modified their holdings of the stock. Fiduciary Alliance LLC grew its stake in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Pfizer in the third quarter worth about $3,019,000. Money Concepts Capital Corp lifted its holdings in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after purchasing an additional 57,188 shares during the period. Vista Investment Partners LLC boosted its position in Pfizer by 236.1% in the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after buying an additional 48,900 shares during the last quarter. Finally, Kepler Cheuvreux Suisse SA purchased a new stake in Pfizer in the third quarter valued at approximately $16,613,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Key Pfizer News

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Phase 3 TALAPRO‑3 topline: the TALZENNA (talazoparib) + XTANDI (enzalutamide) combo met the study’s primary endpoint with a significant improvement in radiographic progression‑free survival for HRR‑mutated metastatic castration‑sensitive prostate cancer — a potential label expansion and commercial upside for Pfizer’s oncology franchise. TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer
• Positive Sentiment: Atirmociclib Phase II success: a second‑line metastatic breast cancer study met its primary endpoint, strengthening Pfizer’s mid‑stage oncology pipeline and adding incremental clinical value that could support future partnerships or asset monetization. PFE’s Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline Push
• Positive Sentiment: Analyst upgrades and bullish forecasts: recent analyst upgrades and an HSBC note highlighting strong upside have coincided with intraday buying and headline momentum, supporting the stock’s short‑term lift. Pfizer (NYSE:PFE) Stock Price Up 3.2% Following Analyst Upgrade
• Positive Sentiment: Income/safety narrative: coverage framing Pfizer as a defensive, dividend‑paying option amid macro and oil volatility is attracting yield‑focused investors. That narrative helps support multiple expansion versus more cyclical sectors. Looking for Safety and Yield as Oil Prices Whip Saw? This Stock Has You Covered.
• Neutral Sentiment: Pfizer vs Moderna sector comparison pieces highlight differing growth drivers (vaccines vs diversified pharma/oncology) but are more background for positioning than immediate stock movers. Pfizer vs Moderna: Which Pharma Stock Has More Upside?
• Neutral Sentiment: Early‑stage study updates: Pfizer advanced a PF‑07328948 liver study (Phase 1) while also closing one early melanoma program — incremental pipeline news that fine‑tunes expectations but doesn’t materially alter the company’s overall revenue base today. Pfizer Advances Early PF-07328948 Liver Study, Adding Quiet Support to PFE’s Pipeline Story
• Negative Sentiment: Program termination: Pfizer ended an early‑stage melanoma study (PF‑08046031), which trims one oncology bet and highlights the usual R&D attrition risk that can temper optimism about pipeline breadth. Pfizer Ends Early-Stage Melanoma Study, Trimming One Oncology Bet But Not The Broader Pipeline

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.